Back to search results

COVID-19 Impact on Financial Costs for Breast Cancer Patients

This study is looking at how the COVID-19 pandemic has affected the money-related challenges, like out-of-pocket costs, lost wages, and unemployment, for women with breast cancer who are having breast surgery. Researchers want to understand if these financial burdens, known as financial toxicity (the negative effects of healthcare costs on well-being), are made worse by the pandemic. You would complete questionnaires to share information about your financial experiences related to your breast cancer treatment, including if you have breast reconstruction. The goal is to show the financial impact of breast surgery and how COVID-19 might play a role.

Study design
This is an observational study aiming to enroll 600 participants. It does not involve different treatment groups.
What's involved
You would complete up to four electronic questionnaires, each taking about 15 minutes, before surgery and then at 6, 12, and 24 months after surgery.
Compensation
Not stated in the trial record.
Follow-up
After completing the study questionnaires, patients will be followed for an additional year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04169542

Impact of COVID-19 Pandemic on Out-of-Pocket Costs, Lost Wages, and Unemployment in Patients With Breast Cancer Undergoing Breast Surgery

Recruiting
Not specifiedAges 18+Observational
M.D. Anderson Cancer Center
~600 participants
Updated 2026-05-04 on ClinicalTrials.gov
What's tested:Questionnaire Administration

At a glance

Recruiting sites
4 of 4 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Prevalence of financial toxicity
Measured over Up to 1 year after completion of study

Conditions

Breast Ductal Carcinoma In Situ
COVID-19 Infection
Hereditary Breast Carcinoma
Invasive Breast Carcinoma

Explore related trials

Breast CarcinomaBreast Ductal Carcinoma In SituHereditary Breast CarcinomaInvasive Breast Carcinoma

Where it's being run

4 sites across 1 states
Texas4

Study leadership

  • Carrie Chu, MD · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center

Who to contact

Carrie Chu, MD
[email protected]
713-794-1247
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Have an indication for surgical treatment of invasive breast cancer or ductal breast carcinoma in situ (DCIS) or prophylaxis in the setting of genetic mutations or strong family history
English-speaking
Able to complete consent
Able to fill out computer survey material

Exclusion

Non-English-speaking
Those with recurrent or metastatic disease or concurrent primary cancers
Patients undergoing breast conservation therapy will also be excluded from the study

What this trial measures

  • Prevalence of financial toxicityUp to 1 year after completion of study

    Will be measured by the Comprehensive Score for financial Toxicity questionnaire. Summary statistics including mean, standard deviation, median, and range for continuous variables, and frequency count and percentage for categorical variables will be provided. Various subgroup analyses may occur. In these cases, continuous variables will be compared using the two-sample t-test and categorical variables will be compared using chi-squared test or Fisher's exact test. Multivariate regression analysis will be performed to account for confounding and to increase the robustness of any causal inference.